Active Not Recruiting
PHASE2
INTERVENTIONAL
NCT06579105
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Detailed Description
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator. The study is planned to be conducted in approximately 15 countries, approximately 90 sites will be involved.
Interventions
Name:
Placebo (placebo matching AZD5004 film-coated tablet)
Type:
DRUG
Description:
Placebo film-coated tablet (matching AZD5004)
Name:
AZD5004
Type:
DRUG
Description:
AZD5004 film-coated tablet, once daily during 26 weeks
Name:
Semaglutide
Type:
DRUG
Description:
3-14 mg tablets of Semaglutide
Primary Outcomes
Measure:
Change in HbA1c
TimeFrame:
Baseline to Week 26
Description:
To evaluate the effect of AZD5004 versus placebo on glycemic control
Trial Information
NCT ID
NCT06579105
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
AstraZeneca
Last Updated
December 15, 2025